Evasion of host immunity directed by papillomavirus-encoded proteins

Virus Research

Volumn 88, Issue 1-2, 2002, Pages 103-117

  O'Brien, Philippa M ^a   Saveria Campo, M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Host immune system; Interferon; Major histocompatibility class I; Papillomavirus

Indexed keywords

INTERFERON; INTERLEUKIN 18; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; ONCOPROTEIN; VIRUS PROTEIN;

ANTIGEN PRESENTATION; CANCER CELL; CARCINOGENESIS; CELL TRANSFORMATION; DOWN REGULATION; EPITHELIUM; EVOLUTION; HOST CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; INFLAMMATION; LIFE CYCLE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PAPILLOMA VIRUS; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS REPLICATION;

FEMALE; HUMANS; IMMUNITY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; VIRAL PROTEINS;

PAPILLOMAVIRUS;

EID: 0036711224     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1702(02)00123-5     Document Type: Review

References (103)

1. Aichinger G., Karlsson L., Jackson M.R., Vestberg M., Vaughan J.H., Teyton L., Lechler R.I., Peterson P.A. Major histocompatibility complex class II-dependent unfolding, transport, and degradation of endogenous proteins. J. Biol. Chem. 272:1997;29127-29136.
2. Alcami A., Koszinowski U.H. Viral mechanisms of immune evasion. Immunol. Today. 21:2000;447-455.
3. Alloub M.I., Barr B.B., McLaren K.M., Smith I.W., Bunney M.H., Smart G.E. Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. Br. Med. J. 298:1989;153-156.
4. Anderson R.A., Scobie L., O'Neil B.W., Grindlay G.J., Campo M.S. Viral proteins of bovine papillomavirus type 4 during the development of alimentary canal tumours. Vet. J. 154:1997;69-78.
5. Arbeit J.M., Munger K., Howley P.M., Hanahan D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J. Virol. 68:1994;4358-4368.
6. Ashrafi G.H., Marchetti B., Sibbet G., Tsirimonaki E., Andrew L., O'Brien P.M., Campo M.S. Down-regulation of surface MHC class I by bovine papillomavirus E5 proteins. Oncogene. 21:2002;428-459.
7. Azoury-Ziadeh R., Herd K., Fernando G.J., Lambert P., Frazer I.H., Tindle R.W. Low level expression of human papillomavirus type 16 (HPV16) E6 in squamous epithelium does not elicit E6 specific B- or T-helper immunological responses, or influence the outcome of immunisation with E6 protein. Virus Res. 73:2001;189-199.
8. Barnard P., McMillan N.A. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology. 259:1999;305-313.
9. Barnard P., Payne E., McMillan N.A. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of inteferon-alpha. Virology. 277:2000;411-419.
10. Bonagura V.R., Siegal F.P., Abramson A.L., Santiago-Schwarz F., O'Reilly M.E., Shah K., Drake D., Steinberg B.M. Enriched HLA-DQ3 phenotype and decreased class I major histocompatibility complex antigen expression in recurrent respiratory papillomatosis. Clin. Diag. Lab. Immunol. 1:1994;357-360.
11. Bonagura V.R., Hatam L., de Voti J., Zeng F., Steinberg B.M. Recurrent respiratory papillomatosis: altered CD8(+) T-cell subsets and T(H)1/T(H)2 cytokine imbalance. Clin. Immunol. 93:1999;302-311.
12. Bontkes H.J., Walboomers J.M., Meijer C.J., Helmerhorst T.J., Stern P.L. Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet. 351:1998;187-188.
13. Borchers A., Braspenning J., Meijer J., Osen W., Gissmann L., Jochmus I. E7-specific cytotoxic T cell tolerance in HPV-transgenic mice. Arch. Virol. 144:1999;1539-1556.
14. Brady C.S., Bartholomew J.S., Burt D.J., Duggan-Keen M.F., Glenville S., Telford N., Little A.M., Davidson J.A., Jimenez P., Ruiz-Cabello F., Garrido F., Stern P.L. Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens. 55:2000;401-411.
15. Burkhardt A., Willingham M., Gay C., Jeang K.T., Schlegel R. The E5 oncoprotein of bovine papillomavirus is oriented asymmetrically in Golgi and plasma membranes. Virology. 170:1989;334-339.
16. Burnett S., Jareborg N., DiMaio D. Localization of bovine papillomavirus type 1 E5 protein to transformed basal keratinocytes and permissive differentiated cells in fibropapilloma tissue. PNAS USA. 89:1992;5665-5669.
17. Campo M.S. Bovine papillomavirus and cancer. Vet. J. 154:1997;175-188.
18. Campo M.S., Grindlay G.J., O'Neil B.W., Chandrachud L.M., McGarvie G.M., Jarrett W.F. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J. Gen. Virol. 74:1993;945-953. Published erratum appears in J. Gen. Virol. 1993 74, 2038.
19. Campo M.S., Jarrett W.F.H., O'Neil B.W., Barron R.J. Latent papillomavirus infection in cattle. Res. Vet. Sci. 56:1994;151-157.
20. Carter J.J., Galloway D.A. Humoral immune response to human papillomavirus infection. Clin. Dermatol. 15:1997;249-259.
21. Chambers M.A., Wei Z., Coleman N., Nash A.A., Stanley M.A. 'Natural' presentation of human papillomavirus type-16 E7 protein to immunocompetent mice results in antigen-specific sensitization or sustained unresponsiveness. Eur. J. Immunol. 24:1994;738-745.
22. Chang Y.E., Laimins L.A. Microarray analysis identified interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J. Virol. 74:2000;4174-4182.
23. Chang J.L., Tsao Y.P., Liu D.W., Huang S.J., Lee W.H., Chen S.L. The expression of HPV-16 E5 protein in squamous neoplastic changes in the uterine cervix. J. Biomed. Sci. 8:2001;206-213.
24. Cho Y.S., Kang J.W., Cho M., Cho C.W., Lee S., Choe Y.K., Kim Y., Choi I., Park S.N., Kim S., Dinarello C.A., Yoon D.Y. Down modulation of IL-18 expression by human papillomavirus type 16 E6. FEBS Lett. 501:2001;139-145.
25. Clerici M., Merola M., Ferrario E., Trabattoni D., Villa M.L., Stefanon B., Venzon D.J., Shearer G.M., de Palo G., Clerici E. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J. Natl. Cancer Inst. 89:1997;245-250.
26. Coleman N., Birley H.D.L., Renton A.M., Hanna N.F., Ryait B.K., Byrne M., Taylor-Robinson D., Stanley M.A. Immunological events in regressing genital warts. Am. J. Clin. Path. 102:1994;768-774.
27. Cresswell P., Bangia N., Dick T., Dietrich G. The nature of the MHC class I peptide loading complex. Immunol. Rev. 172:1999;21-28.
28. De Gruijl T.D., Bontkes H.J., van den Muysenberg A.J., van Oostyeen J.W., Stukart M.J., Verheijen R.H., van der Vange N., Snijders P.J., Meijer C.J., Walboomers J.M., Scheper R.J. Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix. Eur. J. Cancer. 35:1999;490-497.
29. Del Mistro A., Chieco Bianchi L. HPV-related neoplasias in HIV-infected individuals. Eur. J. Cancer. 37:2001;1227-1235.
30. Di Lonardo A., Campo M.S., Venuti A., Marcante M.L. Antibody response to E6, E7 and L1 proteins of human papillomavirus type 16 in an Italian population. J. Med. Virol. 43:1994;357-361.
31. DiMaio D., Mattoon D. Mechanisms of cell transformation by papillomavirus E5 proteins. Oncogene. 20:2001;7866-7873.
32. Doan T., Herd K., Street M., Bryson G., Fernando G., Lambert P., Tindle R. Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles. J. Virol. 73:1999;6166-6170.
33. Doan T., Herd K.A., Lambert P.F., Fernando G.J., Street M.D., Tindle R.W. Peripheral tolerance to human papillomavirus E7 oncoprotein occurs by cross-tolerization, is largely Th-2-independent, and is broken by dendritic cell immunization. Cancer Res. 60:2000;2810-2815.
34. Dunn L.A., Evander M., Tindle R.W., Bulloch A.L., de Kluyver R.L., Fernando G.J., Lambert P.F., Frazer I.H. Presentation of the HPV16 E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal. Virology. 235:1997;94-103.
35. Evander M., Frazer I.H., Payne E., Qi Y.M., Hengst K., McMillan N.A. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J. Virol. 71:1997;2449-2456.
36. Evans E.M., Man S., Evans A.S., Borysiewicz L.K. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res. 57:1997;2943-2950.
37. Evans M., Borysiewicz L.K., Evans A.S., Rowe M., Jones M., Gileadi U., Cerundolo V., Man S. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J. Immunol. 167:2001;5420-5428.
38. Faccini A.M., Cairney M., Ashrafi G.H., Finbow M.E., Campo M.S., Pitts J.D. The bovine papillomavirus type 4 E8 protein binds to ductin and causes loss of gap junctional intercellular communication in primary fibroblasts. J. Virol. 70:1996;9041-9045.
39. Farrell H.E., Vally H., Lynch D.M., Fleming P., Shellam G.R., Scalzo A.A., Davis-Poynter N.J. Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature. 386:1997;510-514.
40. Franchini G., Mulloy J.C., Koralnik I.J., Lo Monico A., Sparkowski J.J., Andresson T., Goldstein D.J., Schlegel R. The human T-cell leukemia/lymphotropic virus type I p12I protein cooperates with the E5 oncoprotein of bovine papillomavirus in cell transformation and binds the 16-kilodalton subunit of the vacuolar H+ ATPase. J. Virol. 67:1993;7701-7704.
41. Frazer I.H., Leippe D.M., Dunn L.A., Liem A., Tindle R.W., Fernando G.J., Phelps W.C., Lambert P.F. Immunological responses in human papillomavirus 16 E6/E7-transgenic mice to E7 protein correlate with the presence of skin disease. Cancer Res. 55:1995;2635-2639.
42. Frazer I.H., Thomas R., Zhou J., Leggatt G.R., Dunn L., McMillan N., Tindle R.W., Filgueira L., Manders P., Barnard P., Sharkey M. Potential strategies utilised by papillomavirus to evade host immunity. Immunol. Rev. 168:1999;131-142.
43. Frazer I.H., de Kluyver R., Leggatt G.R., Guo H.Y., Dunn L., White O., Harris C., Liem A., Lambert P. Tolerance or immunity to a tumor antigen expressed in somatic cells can be determined by systemic proinflammatory signals at the time of first antigen exposure. J. Immunol. 167:2001;6180-6187.
44. Früh K., Grühler A., Krishna R.M., Schoenhals G.J. A comparison of viral immune escape strategies targeting the MHC class I assembly pathway. Immunol. Rev. 168:1999;157-166.
45. Garcia-Millian R., Santos A., Perea S.E., Gonzalez-Cabanas R., Valenzuela C., Arana M. Molecular analysis of resistance to interferon in patients with laryngeal papillomatosis. Cytokines Cell Mol. Ther. 5:1999;79-85.
46. Georgopoulos N.T., Proffitt J.L., Blair G.E. Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene. 19:2000;4930-4935.
47. Goldstein D.J., Finbow M.E., Andresson T., McLean P., Smith K., Bubb V., Schlegel R. Bovine papillomavirus E5 oncoprotein binds to the 16K component of vacuolar H(+)-ATPases. Nature. 352:1991;347-349.
48. Greenberg M.E., Iafrate A.J., Skowronski J. The SH3 domain-binding surface and an acidic motif in HIV-1 Nef regulate trafficking of class I MHC complexes. EMBO J. 17:1998;2777-2789.
49. Gromme M., Uytdehaag F.G., Janssen H., Calafat J., van Binnendijk R.S., Kenter M.J., Tulp A., Verwoerd D., Neefjes J. Recycling MHC class I molecules and endosomal peptide loading. PNAS USA. 96:1999;10326-10331.
50. Gutch M.J., Reich N.C. Repression of the interferon signal transduction pathway by the adenovirus E1A oncogene. PNAS USA. 88:1991;7913-7919.
51. Halpert R., Fruchter R.G., Sedlis A., Butt K., Boyce J.G., Sillman F.H. Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet. Gynecol. 68:1986;251-258.
52. Harwood C.A., Surentheran T., McGregor J.M., Spink P.J., Leigh I.M., Breuer J., Proby C.M. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J. Med. Virol. 61:2000;289-297.
53. Heard I., Tassie J.M., Schmitz V., Mandelbrot L., Kazatchkine M.D., Orth G. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load. Obstet. Gynecol. 96:2000;403-409.
54. Herd K., Fernando G.J., Dunn L.A., Frazer I.H., Lambert P., Tindle R.W. E7 oncoprotein of human papillomavirus type 16 expressed constitutively in the epidermis has no effect on E7-specific B- or Th-repertoires or on the immune response induced or sustained after immunization with E7 protein. Virology. 231:1997;155-165.
55. Hilditch-Maguire P.A., Lieppe D.M., West D., Lambert P.F., Frazer I.H. T cell-mediated and non-specific inflammatory mechanisms contribute to the skin pathology of HPV 16 E6E7 transgenic mice. Intervirology. 42:1999;43-50.
56. Hohn H., Pilch H., Gunzel S., Neukirch C., Hilmes C., Kaufmann A., Seliger B., Maeurer M.J. CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. J. Immunol. 163:1999;5715-5722.
57. Ishido S., Choi J.K., Lee B.S., Wang C., DeMaria M., Johnson R.P., Cohen G.B., Jung J.U. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity. 13:2000;365-374.
58. Jay N., Moscicki A.B. Human papillomavirus infections in women with HIV disease: prevalence, risk, and management. AIDS Read. 10:2000;659-668.
59. Johnson J.M., Nicot C., Fullen J., Ciminale V., Casareto L., Mulloy J.C., Jacobson S., Franchini G. Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein. J. Virol. 75:2001;6086-6094.
60. Kalvakolanu D.V., Bandyopadhyay S.K., Harter M.L., Sen G.C. Inhibition of interferon-inducible gene expression by adenovirus E1A proteins: block in transcriptional complex formation. PNAS USA. 88:1991;7459-7463.
61. Kedzia H., Gozdzicka-Jozefiak A., Wolna M., Tomczak E. Distribution of human papillomavirus 16 in the blood of women with uterine cervix carcinoma. Eur. J. Gynaecol. Oncol. 13:1992;522-526.
62. Kell B., Jewers R.J., Cason J., Pakarian F., Kaye J.N., Best J.M. Detection of E5 oncoprotein in human papillomavirus type 16-positive cervical scrapes using antibodies raised to synthetic peptides. J. Gen. Virol. 75:1994;2451-2456.
63. Kirnbauer R., Chandrachud L.M., O'Neil B.W., Wagner E.R., Grindlay G.J., Armstrong A., McGarvie G.M., Schiller J.T., Lowy D.R., Campo M.S. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 219:1996;37-44.
64. Knowles G., O'Neil B.W., Campo M.S. Phenotypical characterization of lymphocytes infiltrating regressing papillomas. J. Virol. 70:1996;8451-8458.
65. Koizumi H., Sato-Matsumura K.C., Nakamura H., Shida K., Kikkawa S., Matsumoto M., Toyoshima K., Seya T. Distribution of IL-18 and IL-18 receptor in human skin: various forms of IL-18 are produced in keratinocytes. Arch. Dermatol. Res. 293:2001;325-333.
66. Konya J., Dillner J. Immunity to oncogenic human papillomaviruses. Adv. Cancer Res. 82:2001;205-238.
67. Lee S.J., Cho Y.S., Cho M.C., Shim J.H., Lee K.A., Ko K.K., Choe Y.K., Park S.N., Hoshino T., Kim S., Dinarello C.A., Yoon D.Y. Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells. J. Immunol. 167:2001;497-504.
68. Li S., Labrecque S., Gauzzi M.C., Cuddihy A.R., Wong A.H., Pellegrini S., Matlashewski G.J., Koromilas A.E. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene. 18:1999;5727-5737.
69. Loenen W.A., Bruggeman C.A., Wiertz E.J. Immune evasion by human cytomegalovirus: lessons in immunology and cell biology. Semin. Immunol. 13:2001;41-49.
70. Lu X., Yu H., Liu S.H., Brodsky F.M., Peterlin B.M. Interactions between HIV1 Nef and vacuolar ATPase facilitate the internalization of CD4. Immunity. 8:1998;647-656.
71. Mahr J.A., Gooding L.R. Immune evasion by adenoviruses. Immunol. Rev. 168:1999;121-130.
72. Malejczyk J., Majewski S., Jablonska S., Rogozinski T.T., Orth G. Abrogated NK-cell lysis of human papillomavirus (HPV)-16-bearing keratinocytes in patients with pre-cancerous and cancerous HPV-induced anogenital lesions. Int. J. Cancer. 43:1989;209-214.
73. Malejczyk J., Malejczyk M., Majewski S., Orth G., Jablonska S. NK-cell activity in patients with HPV16-associated anogenital tumors: defective recognition of HPV16-harboring keratinocytes and restricted unresponsiveness to immunostimulatory cytokines. Int. J. Cancer. 54:1993;917-921.
74. Marchetti, B., Ashrafi G.H., Tsirimonaki, E., O'Brien, P.M., Campo, M.S. 2002. The papillomavirus oncoprotein E5 retains the major histocompatibility class I in the Golgi apparatus and prevent its transport to the cell surface. Oncogene, in press.
75. Matikainen S., Paananen A., Miettinen M., Kurimoto M., Timonen T., Julkunen I., Sareneva T. IFN-alpha and IL-18 synergistically enhance IFN-gamma production in human NK cells: differential regulation of Stat4 activation and IFN-gamma gene expression by IFN-alpha and IL-12. Eur. J. Immunol. 31:2001;2236-2245.
76. Melero I., Singhal M.C., McGowan P., Haugen H.S., Blake J., Hellstrom K.E., Yang G., Clegg C.H., Chen L. Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J. Virol. 71:1997;3998-4004.
77. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J. Clin. Virol. 19:2000;1-5.
78. Nakanishi K., Yoshimoto T., Tsutsui H., Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Ann. Rev. Immunol. 19:2001;423-474.
79. Nees M., Geoghegan J.M., Hyman T., Frank S., Miller L., Woodworth C.D. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J. Virol. 75:2001;4283-4296.
80. O'Brien V., Campo M.S. BPV-4 E8 transforms NIH 3T3 cells, up-regulates cyclin A and cyclin A-associated kinase activity and de-regulates expression of the cdk inhibitor p27KIP1. Oncogene. 17:1998;293-301.
81. Okabayashi M., Angell M.G., Christensen N.D., Kreider J.W. Morphometric analysis and identification of infiltrating leukocytes in regressing and progressing Shope rabbit papillomas. Int. J. Cancer. 50:1991;919-923.
82. Orth G. Epidermodysplasia verruciformis. Salzman N.P., Howley P.M., The Papovaviridae. 2:1987;199-243 Plenum Press, London.
83. Ozsaran A.A., Ates T., Dikmen Y., Zeytinoglu A., Terek C., Erhan Y., Ozacar T., Bilgic A. Evaluation of the risk of cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant patients receiving immunosuppressive therapy. Eur. J. Gynaecol. Oncol. 20:1999;127-130.
84. Park J.S., Kim E.J., Kwon H.J., Hwang E.S., Namkoong S.E., Um S.J. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J. Biol. Chem. 275:2000;6764-6769.
85. Payne D., Tyring S.K., Doherty M.G., Daya D., Chan T.S. Detection of human papillomavirus type 16 in plasma cells. Gynecol. Oncol. 48:1993;406-412.
86. Pennie W.D., Grindlay G.J., Cairney M., Campo M.S. Analysis of the transforming functions of bovine papillomavirus type 4. Virology. 193:1993;614-620.
87. Reich Z., Altman J.D., Boniface J.J., Lyons D.S., Kozono H., Ogg G., Morgan C., Davis M.M. Stability of empty and peptide-loaded class II major histocompatibility complex molecules at neutral and endosomal pH: comparison to class I proteins. PNAS USA. 94:1997;2495-2500.
88. Ronco L.V., Karpova A.Y., Vidal M., Howley P.M. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 12:1998;2061-2072.
89. Routes J.M., Ryan S., Li H., Steinke J., Cook J.L. Dissimilar immunogenicities of human papillomavirus E7 and adenovirus E1A proteins influence primary tumor development. Virology. 277:2000;48-57.
90. Schapiro F., Sparkowski J., Adduci A., Suprynowicz F., Schlegel R., Grinstein S. Golgi alkalinization by the papillomavirus E5 oncoprotein. J. Cell Biol. 148:2000;305-315.
91. Smith G.L., Symons J.A., Alcami A. Poxviruses: interfering with interferon. Semin. Virol. 8:1998;409-418.
92. Stark G.R., Kerr I.M. Interferon-dependent signaling pathways: DNA elements, transcription factors, mutations, and effects of viral proteins. J. Interferon Res. 12:1992;147-151.
93. Stentella P., Frega A., Ciccarone M., Cipriano L., Tinari A., Tzantzoglou S., Pachi A. HPV and intraepithelial neoplasia recurrent lesions of the lower genital tract: assessment of the immune system. Eur. J. Gynaecol. Oncol. 19:1998;466-469.
94. Stocco dos Santos R.C., Lindsey C.J., Ferraz O.P., Pinto J.R., Mirandola R.S., Benesi F.J., Birgel E.H., Pereira C.A., Becak W. Bovine papillomavirus transmission and chromosomal aberrations: an experimental model. J. Gen. Virol. 79:1998;2127-2135.
95. Straight S.W., Herman B., McCance D.J. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J. Virol. 69:1995;3185-3192.
96. Takeda K., Tsutsui H., Yoshimoto T., Adachi O., Yoshida N., Kishimoto T., Okamura H., Nakanishi K., Akira S. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity. 8:1998;383-390.
97. Thomsen P., van Deurs B., Norrild B., Kayser L. The HPV16 E5 oncogene inhibits endocytic trafficking. Oncogene. 19:2000;6023-6032.
98. Tindle R.W. Human papillomavirus vaccines for cervical cancer. Curr. Opin. Immunol. 8:1996;643-650.
99. Van Leeuwen J.E.M., Kearse K.P. Deglucosylation of N-linked glycans is an important step in the dissociation of calreticulin-class I-TAP complexes. PNAS USA. 93:1996;13997-14001.
100. Vambutas A., Bonagura V.R., Steinberg B.M. Altered expression of TAP-1 and major histocompatibility complex class I in laryngeal papillomatosis: correlation of TAP-1 with disease. Clin. Diagn. Lab. Immunol. 7:2000;79-85.
101. Vambutas A., DeVoti J., Pinn W., Steinberg B.M., Bonagura V.R. Interaction of human papillomavirus type 11 E7 protein with Tap-1 results in the reduction of ATP-dependent peptide transport. Clin. Immunol. 101:2001;94-99.
102. Viola A., Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science. 273:1996;104-106.
103. Wu R., Coleman N., Stanley M. Different susceptibility of cervical keratinocytes containing human papillomavirus to cell-mediated cytotoxicity. Chin. Med. J. 109:1996;854-858.